NEW YORK (GenomeWeb) – CardioDx's 2013 revenues increased more than three-fold year over year, the company said in a regulatory document on Monday.

In an amended preliminary prospectus filed with the US Securities and Exchange Commission, the Palo Alto, Calif.-based cardiovascular molecular diagnostics firm reported $8.0 million in revenues for 2013, compared to $2.5 million in 2012. Test volume last year rose to 22,371 tests performed, up from 9,990 in 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.